These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 12907620)

  • 1. Rapamycin inhibits the interleukin 10 signal transduction pathway and the growth of Epstein Barr virus B-cell lymphomas.
    Nepomuceno RR; Balatoni CE; Natkunam Y; Snow AL; Krams SM; Martinez OM
    Cancer Res; 2003 Aug; 63(15):4472-80. PubMed ID: 12907620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PI3Kδ inhibition augments the efficacy of rapamycin in suppressing proliferation of Epstein-Barr virus (EBV)+ B cell lymphomas.
    Furukawa S; Wei L; Krams SM; Esquivel CO; Martinez OM
    Am J Transplant; 2013 Aug; 13(8):2035-43. PubMed ID: 23841834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual blockade of the PI3K/Akt/mTOR pathway inhibits posttransplant Epstein-Barr virus B cell lymphomas and promotes allograft survival.
    Sang AX; McPherson MC; Ivison GT; Qu X; Rigdon J; Esquivel CO; Krams SM; Martinez OM
    Am J Transplant; 2019 May; 19(5):1305-1314. PubMed ID: 30549430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapamycin inhibits proliferation of Epstein-Barr virus-positive B-cell lymphomas through modulation of cell-cycle protein expression.
    Vaysberg M; Balatoni CE; Nepomuceno RR; Krams SM; Martinez OM
    Transplantation; 2007 Apr; 83(8):1114-21. PubMed ID: 17452903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epstein-Barr virus, rapamycin, and host immune responses.
    Krams SM; Martinez OM
    Curr Opin Organ Transplant; 2008 Dec; 13(6):563-8. PubMed ID: 19060543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Syk-induced phosphatidylinositol-3-kinase activation in Epstein-Barr virus posttransplant lymphoproliferative disorder.
    Hatton O; Lambert SL; Phillips LK; Vaysberg M; Natkunam Y; Esquivel CO; Krams SM; Martinez OM
    Am J Transplant; 2013 Apr; 13(4):883-890. PubMed ID: 23398911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Constitutive activation of Jak/STAT proteins in Epstein-Barr virus-infected B-cell lines from patients with posttransplant lymphoproliferative disorder.
    Nepomuceno RR; Snow AL; Robert Beatty P; Krams SM; Martinez OM
    Transplantation; 2002 Aug; 74(3):396-402. PubMed ID: 12177620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Syk activation of phosphatidylinositol 3-kinase/Akt prevents HtrA2-dependent loss of X-linked inhibitor of apoptosis protein (XIAP) to promote survival of Epstein-Barr virus+ (EBV+) B cell lymphomas.
    Hatton O; Phillips LK; Vaysberg M; Hurwich J; Krams SM; Martinez OM
    J Biol Chem; 2011 Oct; 286(43):37368-78. PubMed ID: 21908615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monomorphic Epstein-Barr virus (EBV)-associated large B-cell posttransplant lymphoproliferative disorder presenting as a tongue ulcer in a pancreatic transplant patient.
    Bruce AJ; Subtil A; Rogers RS; Castro LA
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2006 Oct; 102(4):e24-8. PubMed ID: 16997090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epstein-Barr virus detection in non-Hodgkin's lymphoma of the oral cavity: an immunocytochemical and in situ hybridization study.
    Leong IT; Fernandes BJ; Mock D
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2001 Aug; 92(2):184-93. PubMed ID: 11505266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: A potential approach to prevention and treatment of posttransplant lymphoproliferative disorders.
    Majewski M; Korecka M; Kossev P; Li S; Goldman J; Moore J; Silberstein LE; Nowell PC; Schuler W; Shaw LM; Wasik MA
    Proc Natl Acad Sci U S A; 2000 Apr; 97(8):4285-90. PubMed ID: 10759564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of EBV lymphoma development by oncolytic myxoma virus in a murine xenograft model of post-transplant lymphoproliferative disease.
    Kim M; Rahman MM; Cogle CR; McFadden G
    Biochem Biophys Res Commun; 2015 Jul; 462(4):283-7. PubMed ID: 25843801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients.
    Schubert S; Renner C; Hammer M; Abdul-Khaliq H; Lehmkuhl HB; Berger F; Hetzer R; Reinke P
    J Heart Lung Transplant; 2008 Jan; 27(1):100-5. PubMed ID: 18187094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bcl-2 antisense (G3139, Genasense) enhances the in vitro and in vivo response of Epstein-Barr virus-associated lymphoproliferative disease to rituximab.
    Loomis R; Carbone R; Reiss M; Lacy J
    Clin Cancer Res; 2003 May; 9(5):1931-9. PubMed ID: 12738752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early gene expression changes by Epstein-Barr virus infection of B-cells indicate CDKs and survivin as therapeutic targets for post-transplant lymphoproliferative diseases.
    Bernasconi M; Ueda S; Krukowski P; Bornhauser BC; Ladell K; Dorner M; Sigrist JA; Campidelli C; Aslandogmus R; Alessi D; Berger C; Pileri SA; Speck RF; Nadal D
    Int J Cancer; 2013 Nov; 133(10):2341-50. PubMed ID: 23640782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retinoic acid inhibits IL-6-dependent but not constitutive STAT3 activation in Epstein-Barr virus-immortalized B lymphocytes.
    Zancai P; Cariati R; Quaia M; Guidoboni M; Rizzo S; Boiocchi M; Dolcetti R
    Int J Oncol; 2004 Aug; 25(2):345-55. PubMed ID: 15254731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A population-based study of 135 lymphomas after solid organ transplantation: The role of Epstein-Barr virus, hepatitis C and diffuse large B-cell lymphoma subtype in clinical presentation and survival.
    Kinch A; Baecklund E; Backlin C; Ekman T; Molin D; Tufveson G; Fernberg P; Sundström C; Pauksens K; Enblad G
    Acta Oncol; 2014 May; 53(5):669-79. PubMed ID: 24164103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An HIV protease inhibitor, ritonavir targets the nuclear factor-kappaB and inhibits the tumor growth and infiltration of EBV-positive lymphoblastoid B cells.
    Dewan MZ; Tomita M; Katano H; Yamamoto N; Ahmed S; Yamamoto M; Sata T; Mori N; Yamamoto N
    Int J Cancer; 2009 Feb; 124(3):622-9. PubMed ID: 18973272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. mTOR inhibitors induce cell-cycle arrest and inhibit tumor growth in Epstein-Barr virus-associated T and natural killer cell lymphoma cells.
    Kawada J; Ito Y; Iwata S; Suzuki M; Kawano Y; Kanazawa T; Siddiquey MN; Kimura H
    Clin Cancer Res; 2014 Nov; 20(21):5412-22. PubMed ID: 25208880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epstein-Barr virus-specific T cells for the management of Epstein-Barr virus lymphomas.
    Finberg RW
    Curr Opin Oncol; 2001 Sep; 13(5):349-53. PubMed ID: 11555711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.